Brokerages Assign Cogent Biosciences Target Price of $19.67

Shares of Cogent Biosciences, Inc. (NASDAQ: COGT) received an average recommendation of “Moderate Buy” from fourteen brokerages currently covering the firm, according to data from MarketBeat. The analysis revealed a mix of ratings: one analyst issued a sell recommendation, four rated the stock as hold, seven recommended buy, and two provided strong buy ratings. The average target price set by analysts for the next twelve months stands at $19.67.

Several brokerages have recently updated their price targets for Cogent Biosciences. On August 6, 2023, HC Wainwright reduced its price target from $22.00 to $21.00, while maintaining a buy rating. The following day, JPMorgan Chase & Co. increased its price target from $29.00 to $30.00, assigning an “overweight” rating. Meanwhile, Robert W. Baird raised its price target from $7.00 to $9.00 and provided a neutral rating on July 8, 2023. On July 7, 2023, Leerink Partners adjusted its target from $16.00 to $18.00 with an outperform rating. Lastly, Weiss Ratings reiterated a “sell (e+)” rating on October 8, 2023.

Cogent Biosciences Stock Performance

As of Thursday, shares of COGT opened at $16.22. Over the past year, the stock has fluctuated significantly, with a low of $3.72 and a high of $17.00. Cogent Biosciences currently has a market capitalization of $1.85 billion, a price-to-earnings (P/E) ratio of -9.11, and a beta of 0.30. The company’s fifty-day moving average is $13.44, while its 200-day moving average stands at $9.41.

On August 5, 2023, Cogent Biosciences reported its quarterly earnings, revealing an earnings per share (EPS) of ($0.53), surpassing analysts’ consensus estimate of ($0.55) by $0.02. Analysts predict that the company will post an EPS of ($2.42) for the current financial year.

About Cogent Biosciences

Based in the biotechnology sector, Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Its leading product candidate, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor designed to target specific mutations within the KIT receptor tyrosine kinase. This includes the KIT D816V mutation associated with systemic mastocytosis, as well as other mutations found in patients with advanced gastrointestinal stromal tumors.

The stock market performance and strategic updates from brokerages indicate a growing interest in Cogent Biosciences as it continues to navigate its path in the biotechnology landscape. Investors are keeping a close watch on developments, particularly as the company works to advance its product candidates in a competitive market.